The report, Impossible to escape: The need for stronger restrictions on the placement of alcohol marketing in Australia released by the Public Health Advocacy Institute of WA (PHAIWA) at Curtin University, found almost two-thirds of complaints made to the Alcohol Advertising Review Board (AARB) over the past seven years had raised concerns about the placement of alcohol marketing in Australia.
The report found that 760 of the total 1126 complaints were about where alcohol marketing was placed in the community. Of the 760 placement-related complaints, almost 40% raised concerns that the advertisements were placed where young people were likely to be exposed or with content that would appeal to them. The report highlights the need for governments to introduce stronger restrictions to better protect children and young people from exposure to alcohol marketing.
The full report is available on the AARB website
Campaigners say medicinal cannabis being used as ‘Trojan horse’ towards legalisation. Ireland is “sleepwalking” into the legalisation of cannabis on the back of a campaign of misinformation about the drug, according to doctors who have set up a new group to campaign against liberalisation.
The initial 20 members of the Cannabis Risk Alliance include the head of the College of Psychiatrists, Dr John Hillery, and former president of the Irish Medical Organisation Dr Ray Walley.
Criticising the “one-sided debate” on cannabis, the doctors say society has “taken its eye off the ball” in relation to the harmful effects of the drug.
In their practice, they say they are treating ever-growing numbers of patients suffering a range of side effects from abusing the drug.
For complete story
Abstract: The goal of this study was to investigate Cannabidiol (CBD) hepatotoxicity in 8-week-old male B6C3F1mice. Animals were gavaged with either 0, 246, 738, or 2460 mg/kg of CBD (acute toxicity, 24 h) or with daily doses of 0, 61.5, 184.5, or 615 mg/kg for 10 days (sub-acute toxicity). These doses were the allometrically scaled mouse equivalent doses (MED) of the maximum recommended human maintenance dose of CBD in EPIDIOLEX®(20 mg/kg). In the acute study, significant increases in liver-to-body weight (LBW) ratios, plasma ALT, AST, and total bilirubin were observed for the 2460 mg/kg dose. In the sub-acute study, 75% of mice gavaged with 615 mg/kg developed a moribund condition between days three and four. As in the acute phase, 615 mg/kg CBD increased LBW ratios, ALT, AST, and total bilirubin. Hepatotoxicity gene expression arrays revealed that CBD differentially regulated more than 50 genes, many of which were linked to oxidative stress responses, lipid metabolism pathways and drug metabolizing enzymes.
In conclusion, CBD exhibited clear signs of hepatotoxicity, possibly of a cholestatic nature. The involvement of numerous pathways associated with lipid and xenobiotic metabolism raises serious concerns about potential drug interactions as well as the safety of CBD.
Download Full Report
The Union filed a grievance due to alleged discrimination of the employer against Mr. Tizzard due to his disability. However, Arbitrator Roil concluded that medical cannabis use creates a risk of employer impairment at work and cited lack of available technology to measure cannabis-induced impairment and manage associated risks, causing undue hardship for the employer. Therefore, the grievance filed by the Union was dismissed.
For complete story
The Need for Regulation: It is critical that regulators investigate these problematic marketing practices across all marijuana brands, not just MedMen, to ensure that health claims are independently verified and youth are protected from marijuana marketing. Precedent exists for federal action to regulate MedMen’s national marketing strategy because the responsibility to regulate “products containing cannabis and cannabis-derived compounds” currently rests with the FDA under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act.
For complete article JAMA. Published online May 16, 2019. doi: